Saturday, December 12, 2015

Lilly’s Lung-Cancer Drug Portrazza to Cost $11,430 a Month

From the Wall Street Journal:   Eli Lilly & Co. said Friday its new lung-cancer drug will cost about $11,430 a patient a month in the U. S.—well above what a group of doctors say is a fair price that reflects what they call the drug’s modest benefit.


The Big Pharma company Lilly

is making things awfully chilly

for lung cancer martyrs --

they charge 'em, for starters,

a fortune for drugs willy-nilly.

No comments:

Post a Comment